New hope for tough leukemia: Triple-Drug attack enters early testing
NCT ID NCT06454409
Summary
This early-stage study is testing the safety and best dose of a new three-drug combination for adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to prior treatments. The goal is to see if adding the drug regorafenib to two existing drugs (venetoclax and azacitidine) is safe and can help control the cancer. The study is currently suspended and will involve about 20 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.